Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Axillary Hyperhidrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2016, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape. Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 6 respectively for Axillary Hyperhidrosis. Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology). - The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Axillary Hyperhidrosis Overview 6 Therapeutics Development 7 Pipeline Products for Axillary Hyperhidrosis - Overview 7 Axillary Hyperhidrosis - Therapeutics under Development by Companies 8 Axillary Hyperhidrosis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Axillary Hyperhidrosis - Products under Development by Companies 11 Axillary Hyperhidrosis - Companies Involved in Therapeutics Development 12 Allergan Plc 12 Brickell Biotech, Inc. 13 Dermira Inc. 14 GlaxoSmithKline Plc 15 Revance Therapeutics, Inc. 16 TheraVida, Inc. 17 Axillary Hyperhidrosis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 (oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 ANT-1403 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 botulinum toxinA - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 daxibotulinumtoxinA - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 glycopyrronium tosylate - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 sofpironium bromide - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 umeclidinium bromide - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Axillary Hyperhidrosis - Dormant Projects 41 Axillary Hyperhidrosis - Product Development Milestones 42 Featured News & Press Releases 42 Jun 01, 2016: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis 42 Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating 45 Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis 46 Jan 07, 2016: Dermira Provides DRM04 Development Program Update 47 Dec 23, 2015: Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 47 Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis 49 Sep 28, 2015: Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines 49 Sep 09, 2015: Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 50 Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis 51 Jun 03, 2015: Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate 52 Feb 05, 2015: Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis 52 Jan 12, 2015: Revance Therapeutics Provides Clinical Program Milestone Update For RT001 54 Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis 54 Mar 19, 2014: Anterios Announces Development Of Next Generation Injectable Botulinum Product 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Number of Products under Development for Axillary Hyperhidrosis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Axillary Hyperhidrosis - Pipeline by Allergan Plc, H2 2016 12 Axillary Hyperhidrosis - Pipeline by Brickell Biotech, Inc., H2 2016 13 Axillary Hyperhidrosis - Pipeline by Dermira Inc., H2 2016 14 Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H2 2016 15 Axillary Hyperhidrosis - Pipeline by Revance Therapeutics, Inc., H2 2016 16 Axillary Hyperhidrosis - Pipeline by TheraVida, Inc., H2 2016 17 Assessment by Monotherapy Products, H2 2016 18 Assessment by Combination Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Axillary Hyperhidrosis - Dormant Projects, H2 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.